scholarly journals Age and Cancer Treatment Are Related to Receiving Treatment Summaries and Survivorship Care Plans in Female Young Adult Cancer Survivors

2017 ◽  
Vol 6 (4) ◽  
pp. 573-578 ◽  
Author(s):  
Ksenya Shliakhtsitsava ◽  
Sally A. D. Romero ◽  
Brian W. Whitcomb ◽  
Jessica R. Gorman ◽  
Samantha Roberts ◽  
...  
Keyword(s):  
Young Adult ◽  
Cancer Survivors ◽  
Cancer Treatment ◽  
Survivorship Care Plans ◽  
Survivorship Care ◽  
Treatment Summaries ◽  
Care Plans ◽  
Young Adult Cancer Survivors ◽  
Adult Cancer Survivors ◽  
Young Adult Cancer

Relationship of age and cancer treatment to receiving treatment summaries and survivorship care plans in female young adult cancer survivors.

2017 ◽  
Vol 35 (5_suppl) ◽  
pp. 55-55
Author(s):  
Ksenya Shliakhtsitsava ◽  
Sally A. D. Romero ◽  
Samantha Roberts ◽  
Irene Su
Keyword(s):  
Bone Marrow ◽  
Cancer Survivors ◽  
Cancer Treatment ◽  
Survivorship Care Plans ◽  
Survivorship Care ◽  
Care Plans ◽  
Young Adult Cancer Survivors ◽  
Younger Age ◽  
Adult Cancer Survivors ◽  
Young Adult Cancer

55 Background: For cancer survivors who were diagnosed with cancer during childhood, adolescence and young adulthood years, transitioning into survivorship and post-cancer treatment care remains challenging and may be aided by treatment summaries (TS) and/or survivorship care plans (SCP). Little research has been conducted on receipt of SCP and/or TS from the patient perspective. The objective of this study was to determine patient- and cancer-specific characteristics that are associated with receipt of SCP and/or TS (SCP/TS). Methods: 240 female young adult cancer survivors (YCS) between ages 18-44 were recruited to a national cohort study on reproductive health and completed a web-based survey that included report of receiving SCP and TS. We used logistic regression models to estimate odds ratios (OR) for characteristics associated with receipt of SCP/TS. Results: Mean age (standard deviation) was 32.8 (5.8) years; mean age at cancer diagnosis was 27.2 (7.1) years. Forty-eight (20%) participants were diagnosed with cancer at < 21 years of age. Only 47% of participants reported receipt of SCP/TS. In unadjusted analyses, current age, younger age at diagnosis, education level, receiving chemotherapy and receiving bone marrow transplant were significantly associated with report of SCP/TS receipt. In multivariable analyses, survivors diagnosed at younger age ( < 21 years) had 2-fold higher odds of SCP/TS receipt (OR 2.0, 95% CI 1.0-3.9). Chemotherapy treatment (OR 2.3, 95% CI 1.2-4.6) and bone marrow transplantation (OR 7.2, 95% CI 1.5-33.3) were also significantly associated with SCP/TS receipt. Conclusions: A significant proportion of YCS do not recall receiving a TS or SCP to aid in the transition to post-cancer treatment survivorship care. Receipt of these documents is not uniform across the young cancer survivor population. Improved integration of TS and SCP into cancer survivorship care is needed.

scholarly journals Beyond Premature Ovarian Insufficiency: Staging Reproductive Aging in Adolescent and Young Adult Cancer Survivors

2020 ◽  
Author(s):  
Alexa C O Medica ◽  
Brian W Whitcomb ◽  
Ksenya Shliakhsitsava ◽  
Andrew C Dietz ◽  
Kelsey Pinson ◽  
...  
Keyword(s):  
Young Adult ◽  
Cancer Survivors ◽  
Cancer Treatment ◽  
Adolescent And Young Adult ◽  
Reproductive Aging ◽  
Young Adult Cancer Survivors ◽  
Adult Cancer Survivors ◽  
Advanced Stages ◽  
Young Adult Cancer ◽  
Aging Stage

Abstract Context Although stages of reproductive aging for women in the general population are well described by STRAW+10 criteria, this is largely unknown for female adolescent and young adult cancer survivors (AYA survivors). Objective This work aimed to evaluate applying STRAW + 10 criteria in AYA survivors using bleeding patterns with and without endocrine biomarkers, and to assess how cancer treatment gonadotoxicity is related to reproductive aging stage. Design The sample (n = 338) included AYA survivors from the Reproductive Window Study cohort. Menstrual bleeding data and dried-blood spots for antimüllerian hormone (AMH) and follicle-stimulating hormone (FSH) measurements (Ansh DBS enzyme-linked immunosorbent assays) were used for reproductive aging stage assessment. Cancer treatment data were abstracted from medical records. Results Among participants, mean age 34.0 ± 4.5 years and at a mean of 6.9 ± 4.6 years since cancer treatment, the most common cancers were lymphomas (31%), breast (23%), and thyroid (17%). Twenty-nine percent were unclassifiable by STRAW + 10 criteria, occurring more frequently in the first 2 years from treatment. Most unclassifiable survivors exhibited bleeding patterns consistent with the menopausal transition, but had reproductive phase AMH and/or FSH levels. For classifiable survivors (48% peak reproductive, 30% late reproductive, 12% early transition, 3% late transition, and 7% postmenopause), endocrine biomarkers distinguished among peak, early, and late stages within the reproductive and transition phases. Gonadotoxic treatments were associated with more advanced stages. Conclusions We demonstrate a novel association between gonadotoxic treatments and advanced stages of reproductive aging. Without endocrine biomarkers, bleeding pattern alone can misclassify AYA survivors into more or less advanced stages. Moreover, a large proportion of AYA survivors exhibited combinations of endocrine biomarkers and bleeding patterns that do not fit the STRAW + 10 criteria, suggesting the need for modified staging for this population.

Sign in / Sign up

Export Citation Format

Share Document